Close Menu

NEW YORK (GenomeWeb) – Curetis today posted an 8 percent year-over-year drop in 2017 revenues as an increase in sales of test cartridges for its Unyvero molecular diagnostic instrument was offset by a decline in system and service sales.

For the year ended Dec. 31, 2017, Curetis' revenues fell to €1.2 million ($1.4 million) from €1.3 million in 2016. Cartridge sales in 2017 were €736,000 versus €573,000 the year before, while instrument and service sales fell to €465,000 from €738,000.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.